COCO Stock Analysis: Vita Coco | NASDAQ
Beverages - Non-Alcoholic | NASDAQ, USA | Market Cap: 3.779m USD | 12M Return: 93.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.7M
EPS Trend: 78.7%
Qual. Beats: 1
Rev. Trend: 94.7%
Qual. Beats: 6
Warnings
No concerns identified
Tailwinds
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Vita Coco Company, Inc. is a New York-headquartered beverage company that develops, manufactures, markets, and distributes coconut water products under the Vita Coco brand across the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific. Its product portfolio spans coconut water, oil, and juice, along with adjacent offerings including Vita Coco Treats (a plant-based dairy alternative), Vita Coco Coconut MLK, PWR LIFT (a protein-infused fitness drink), and the Farmers Organic brand, while also supplying private-label products to retailers. Distribution is conducted through club, food, drug, mass, convenience, e-commerce, and foodservice channels. The company was originally incorporated in 2004 as All Market Inc., was renamed The Vita Coco Company, Inc. in September 2021, and trades on NASDAQ under the ticker COCO after its October 2021 IPO.
Operating within the Consumer Staples sector and the Soft Drinks & Non-alcoholic Beverages sub-industry, Vita Coco benefits from exposure to two durable consumer trends: the shift toward naturally hydrating, functional beverages and the broader mainstreaming of plant-based dairy alternatives, both of which support demand for its coconut-derived product range across retail and foodservice channels.
- Coconut input cost inflation pressures gross margins
- International expansion fuels double-digit revenue growth
- Private label competition intensifies in coconut water category
| Net Income: 82.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 4.89 > 1.0 |
| NWC/Revenue: 49.57% < 20% (prev 48.22%; Δ 1.35% < -1%) |
| CFO/TA 0.15 > 3% & CFO 72.6m > Net Income 82.9m |
| Net Debt (-189.0m) to EBITDA (107.4m): -1.76 < 3 |
| Current Ratio: 3.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.5m) vs 12m ago 0.83% < -2% |
| Gross Margin: 37.20% > 18% (prev 37.24%; Δ -0.04% > 0.5%) |
| Asset Turnover: 151.0% > 50% (prev 139.4%; Δ 11.61% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.67 (Total Current Assets 449.7m - Total Current Liabilities 123.2m) / Total Assets 488.3m |
| B: 0.53 (Retained Earnings 258.5m / Total Assets 488.3m) |
| C: 0.24 (EBIT TTM 106.0m / Avg Total Assets 436.2m) |
| D: 2.59 (Book Value of Equity 352.2m / Total Liabilities 136.2m) |
| Altman-Z'' = 10.46 = AAA |
| DSRI: 1.28 (Receivables 120.8m/76.8m, Revenue 658.6m/535.2m) |
| GMI: 1.00 (GM 37.24% / 37.20%) |
| AQI: 0.77 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.23 (Revenue 658.6m / 535.2m) |
| TATA: 0.02 (NI 82.9m - CFO 72.6m) / TA 488.3m) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of July 10, 2026, the stock is trading at USD 71.25 with a total of 1,253,928 shares traded. Over the past week, the price has changed by +3.29%, over one month by -4.00%, over three months by +45.91% and over the past year by +93.82%.
Current recommended Stop Loss: 66.50 (which is 6.7% or 1.2 ATR below the current price).
Vita Coco has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy COCO.
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 75.1 | 5.4% |
P/E Trailing = 47.942
P/E Forward = 28.8184
P/S = 5.7371
P/B = 10.7293
Revenue TTM = 658.6m USD
EBIT TTM = 106.0m USD
EBITDA TTM = 107.4m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.73m USD (from shortTermDebt, last fiscal year)
Debt = 12.9m USD (from shortLongTermDebtTotal, last quarter) (leases 12.9m already included)
Net Debt = -189.0m USD (calculated: Debt 12.9m - CCE 201.9m)
Enterprise Value = 3.59b USD (3.78b + Debt 12.9m - CCE 201.9m)
Interest Coverage Ratio = unknown (Ebit TTM 106.0m / Interest Expense TTM 0.0)
EV/FCF = 55.63x (Enterprise Value 3.59b / FCF TTM 64.5m)
FCF Yield = 1.80% (FCF TTM 64.5m / Enterprise Value 3.59b)
FCF Margin = 9.80% (FCF TTM 64.5m / Revenue TTM 658.6m)
Net Margin = 12.59% (Net Income TTM 82.9m / Revenue TTM 658.6m)
Gross Margin = 37.20% ((Revenue TTM 658.6m - Cost of Revenue TTM 413.6m) / Revenue TTM)
Gross Margin QoQ = 39.68% (prev 34.54%)
Tobins Q-Ratio = 7.35 (Enterprise Value 3.59b / Total Assets 488.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 12.9m)
Taxrate = 21.82% (23.1m / 106.0m)
NOPAT = 82.9m (EBIT 106.0m * (1 - 21.82%))
Current Ratio = 3.65 (Total Current Assets 449.7m / Total Current Liabilities 123.2m)
Debt / Equity = 0.04 (Debt 12.9m / totalStockholderEquity, last quarter 352.2m)
Debt / EBITDA = -1.76 (Net Debt -189.0m / EBITDA 107.4m)
Debt / FCF = -2.93 (Net Debt -189.0m / FCF TTM 64.5m)
Total Stockholder Equity = 326.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.01% (Net Income 82.9m / Total Assets 488.3m)
RoE = 25.43% (Net Income TTM 82.9m / Total Stockholder Equity 326.1m)
RoCE = 29.04% (EBIT 106.0m / Capital Employed (Total Assets 488.3m - Current Liab 123.2m))
RoIC = 24.83% (NOPAT 82.9m / Invested Capital 334.0m)
WACC = 7.87% (E(3.78b)/V(3.79b) * Re(7.90%) + D(12.9m)/V(3.79b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 0.72%
[DCF] Terminal Value 77.97% ; FCFF base≈51.5m ; Y1≈59.0m ; Y5≈86.9m
[DCF] Fair Price = 26.20 (EV 1.31b - Net Debt -189.0m = Equity 1.50b / Shares 57.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 78.75 | EPS CAGR: 23.56% | SUE: 3.33 | # QB: 1
Revenue Correlation: 94.75 | Revenue CAGR: 12.33% | SUE: 3.36 | # QB: 6
EPS current Quarter (2026-06-30): EPS=0.54 | Chg30d=+0.00% | Revisions=+40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.50 | Chg30d=+0.00% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=1.78 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+33.9% | GrowthRev=+20.6%
EPS next Year (2027-12-31): EPS=2.05 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+15.2% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +36% (up=6, down=2)